NewAmsterdam Pharma says EMA panel backs EU approval for Ubeslo, Evlarco cholesterol drugs

NAMS•2026-07-24

CHMP backs EU marketing authorization

NewAmsterdam Pharma says it has secured a positive CHMP opinion recommending EU marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib-ezetimibe) in primary hypercholesterolemia.

European Commission decision and commercialization rights

The company said a European Commission decision is expected in 2H26, setting up a potential European launch with Menarini holding exclusive regional commercialization rights.

NewAmsterdam Pharma says EMA panel backs EU approval for Ubeslo, Evlarco cholesterol drugs

CHMP backs EU marketing authorization

European Commission decision and commercialization rights

Related News

Copper edges higher, heads for weekly gain as non-US stocks tighten

Robin Energy prices 750,000-share public offering at $4 per share

Global Partners to host second-quarter 2026 results conference call

Mobileye publishes transcript of second-quarter 2026 earnings call

BUZZ-Sensient Technologies gains after Q2 results beat